LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Paragon 28 Acquires Additive Orthopaedics
Company News

Paragon 28 Acquires Additive Orthopaedics

June 25, 2021 1 min read Premium comments

Advertisement

#paragon28Secondary#additiveorthopaedics#footandanklesurgery

Englewood, Colorado-based Paragon 28®, Inc., an orthopedic foot and ankle company, has acquired the assets of Little Silver, New Jersey-based Additive Orthopaedics, LLC.

Founded in 2010, Paragon 28 focuses on all things foot and ankle. According to its website, the company’s systems have supported 100,696 surgeries and it has filed 175 patents.

Additive Orthopaedics works with orthopedic surgeons and foot and ankle specialists to create advanced 3D-printed technologies to aid both surgeons and their patients. Per its website, the company “leverages state-of-the-art 3D metal printing technology to design, manufacture, and market patient specific and off the shelf implants specializing in complex reconstructions, implant revisions, and limb salvage.”

Paragon 28’s acquisition includes the U.S. Food and Drug Administration (FDA) approved 3D-printed Patient Specific Talus Spacer for the treatment of avascular necrosis. The FDA approved the device as a humanitarian use device on February 17, 2021. According to the press release, the device is the “first and only patient-specific total talus replacement implant authorized for use in the United States.”

Paragon 28 has also acquired Game Plan®, a “proprietary pre-operative surgical planning application.” The application allows for cloud-based communication between surgeons and engineers to create “patient specific surgical plans and implants.”

Paragon 28 Co-Founder and CEO Albert DaCosta commented on the acquisition, “The addition of the Additive Orthopaedics product portfolio and surgical planning capabilities provides Paragon 28 customers exclusive access to the only FDA-approved patient specific total talus replacement implant.”

DaCosta continued, “The Additive [Orthopaedics] acquisition also significantly accelerates the Company’s [Paragon 28] strategy to leverage smart tools, artificial intelligence, and advanced technology to improve patient outcomes.”

The acquisition comes shortly after Paragon 28’s announcement that it signed a $70 million credit facility with MidCap Financial. For OTW’s coverage of the announcement, see “Paragon 28 Signs 70MM Credit Facility with MidCap Financial.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy